4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Cardiovascular by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 8703 ongoing clinical trials involving Cardiovascular
Of the 8703 trials,2864 trials are in Phase III
Furthermore, 2347 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Cardiovascular by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Cardiovascular therapy area. The largest number of ongoing clinical trials for indications related to cardiovascular therapy area is conducted in the Asia-Pacific region. Europeand North Americaare among some of the other prominent regions involved in drug trials.

Yonsei University: The leading ongoing clinical trial sponsor for indications related to cardiovascular therapy area

Yonsei Universityis the top clinical trial sponsor for indications related to the cardiovascular therapy area.

Assistance Publique - Hopitaux de Paris, Vanderbilt University Medical Center, and Beijing Anzhen Hospital are a few other notable clinical trials sponsors involved in Cardiovascular therapy area. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cardiovascular

Adalimumab (Humira), Apixaban (Eliquis), and Rivaroxaban (Xarelto) are among the key marketed drugs marketed for the treatment of indications related to the cardiovascular therapy area.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as an injection for subcutaneous route of administration. Adalimumab is marketed for the treatment of several indications including Pyoderma Gangrenosum, Axial Spondyloarthritis, Hidradenitis Suppurativa, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Anterior Uveitis, Behcet Disease, Intermediate Uveitis, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Posterior Uveitis. It was first approved in 2002 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including AbbVieInc, EisaiCoLtd, and Abbott Laboratories.

Apixaban (Eliquis) is a phenylpiperidine derivative, acts as antithrombotic or anticoagulant agent. It functions via Coagulation Factor X (Stuart Prower Factor or Stuart Factor or F10 or EC 3.4.21.6) Inhibitor mechanism of action. Apixaban is formulated as tablets and film-coated tablets for oral route of administration. Eliquis ismarketed for the treatment of several indications including Venous Thromboembolism, Stroke, Ischemic Stroke, Pulmonary Embolism, Hemorrhage, Deep Vein Thrombosis (DVT), Thromboembolism, and Venous (Vein) Thrombosis. Apixaban was first approved in 2011and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Pfizer Inc, and Bristol-Myers Squibb Co.